P/B
0,9
Arvinas
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
$499.6M
Market Cap • 10/9/2026
2013
(13 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
1,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
76,4
BVPS
8,6
EPS
0,1
Market Cap
Market Cap
499,6M
EV
-60,3M
EV/Revenue
-0,2
EV/EBITDA
4
EV/EBIT
3,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Retained Earnings
-1,5B
Profitability
Gross Margin
97,2%
EBITDA Margin
—
EBIT Margin
—
Net Margin
2,9%
D&A/EBITDA
0%
R&D/Revenue
75,4%
Capex/Revenue
0,6%
Capex/D&A
62,1%
Capex/OCF
-0,9%
SBC/OCF
—
% PPE
1,8%
% Goodwill
0%
ROE
1,6%
ROIC
—
Growth
CAGR Revenue 5Y
72,4%
CAGR Op. Income 5Y
-36%
CAGR OCF 5Y
8,5%
Leverage
N.D./EBITDA
36,8
Debt/Equity
0%
Current Ratio
7,9
Quick Ratio
7,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!